Black Diamond Therapeutics (BDTX) Total Non-Current Liabilities (2018 - 2020)
Black Diamond Therapeutics' (BDTX) quarterly Total Non-Current Liabilities came in at $21.9 million in Q4 2020, up 350.59% YoY from $4.9 million in Q1 2020, and up 14.78% on a QoQ basis from $19.1 million in Q3 2020.
Black Diamond Therapeutics (BDTX) Total Non-Current Liabilities (2018 - 2020) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 3 years of Total Non-Current Liabilities data on file, last reported at $21.9 million in Q4 2020.
- Quarterly Total Non-Current Liabilities rose 350.59% year-over-year to $21.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $21.9 million (up 350.59% YoY) and the FY2020 annual result came in at $21.9 million, up 350.59% from the prior year.
- Total Non-Current Liabilities advanced to $21.9 million in Q4 2020, from $19.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $21.9 million in Q4 2020 to a low of $2.6 million in Q4 2018.
- A 3-year average of $10.4 million and a median of $6.9 million in 2020 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2019 — Total Non-Current Liabilities surged 88.85% — and 2020, when it soared 350.59%.
- Tracing BDTX's Total Non-Current Liabilities over 3 years: stood at $2.6 million in 2018, then surged by 88.85% to $4.9 million in 2019, then soared by 350.59% to $21.9 million in 2020.
- The last three Total Non-Current Liabilities figures came in at $21.9 million (Q4 2020), $19.1 million (Q3 2020), and $6.3 million (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 21.91 Mn |
| Sep 30, 2020 | 19.09 Mn |
| Jun 30, 2020 | 6.33 Mn |
| Mar 31, 2020 | 7.54 Mn |
| Dec 31, 2019 | 4.86 Mn |
| Dec 31, 2018 | 2.58 Mn |